Does oral BPC-157 actually work beyond the gut? A closer look

What's this video probably claiming?

Based on the caption, @drdrewtimmermans is pushing back on a popular belief in peptide communities: that injectable BPC-157 is the only route for systemic musculoskeletal benefits, while oral BPC-157 is limited to gut repair. The creator appears to be arguing that oral BPC-157 has broader systemic bioavailability than most people assume, positioning it as an exception to the general rule that peptides degrade in the gastrointestinal tract before reaching circulation. This is a nuanced claim that sounds reasonable on the surface, and it's partly grounded in real science. But the jump from "survives digestion" to "works systemically like injectable" is where things get complicated. Given the hashtag category includes TB-500, CJC-1295, and ipamorelin, the broader framing here is almost certainly pro-peptide therapy, which is worth keeping in mind when evaluating how the evidence gets presented.

What does the science actually show?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein found in gastric juice. The stability claim has some real backing. Sikirić et al. published extensively in journals like Current Pharmaceutical Design (2018) showing BPC-157 resists enzymatic breakdown in gastric acid conditions, which is genuinely unusual for peptides. Animal studies, primarily in rats, have demonstrated that oral BPC-157 at doses around 10 mcg/kg to 10 mg/kg produced effects on tendon healing, bone repair, and even neurological outcomes, not just gut tissue. A 2019 paper by Gwyer et al. in Current Opinion in Pharmacology reviewed these wound-healing effects and found the preclinical data reasonably consistent across administration routes. That said, the leap to human bioavailability is not supported by published clinical trials. There are zero completed Phase II or Phase III human trials for BPC-157 in any form as of early 2025. Every citation you'll see is animal data or in vitro work.

Where does the social media noise diverge from clinical reality?

Here's the problem with the "oral BPC works systemically" narrative circulating on TikTok and peptide forums. Animal models, especially rodent studies, are notoriously poor predictors of human GI absorption for peptides. The rat gastric environment differs meaningfully from human physiology in ways that affect peptide transit and mucosal uptake. When creators cite Sikirić's lab work, they're often citing research where the same group both develops and tests the compound, which is a real conflict-of-interest flag in evidence evaluation. More importantly, systemic plasma concentrations after oral dosing have not been measured in humans. Nobody has run a pharmacokinetic study showing that oral BPC-157 clears the intestinal wall and reaches muscle or tendon tissue in humans at therapeutically relevant concentrations. Claiming oral BPC-157 is bioequivalent to injectable for systemic use, even implicitly, goes well beyond what the data supports. The bar for "exception to the rule" should be human PK data, not extrapolated rat studies.

What should you actually know?

BPC-157 is not FDA-approved in any form. It was placed on the FDA's list of bulk drug substances that may not be compounded in 2022, specifically citing insufficient evidence of clinical utility and safety. That regulatory context matters enormously when evaluating TikTok content from peptide-adjacent creators. The oral versus injectable debate is somewhat moot from a regulatory standpoint in the US right now. What's worth understanding is that the stability-in-acid claim is the most defensible part of what this video appears to argue. BPC-157 does appear more acid-stable than most peptides. Whether that translates to meaningful systemic absorption in humans is genuinely unknown. If you're considering BPC-157, the honest answer is that the preclinical data is interesting, the human evidence is absent, and any provider claiming certainty about oral systemic effects is working well ahead of the published science. A regulated telehealth provider should be transparent about that gap, not paper over it.